Cosmo Highlights Strategic AI and GI Innovation Agenda at Digestive Disease Week(R) 2025
Cosmo (CMOPF) is participating in Digestive Disease Week® (DDW) 2025 in San Diego, California from May 3-6. The company's leadership team is conducting strategic meetings with key opinion leaders, innovators, and potential partners in AI and gastrointestinal (GI) drug development. DDW, attracting over 13,000 gastroenterologists, researchers, and industry leaders annually, serves as a platform for Cosmo to advance its position in AI-powered endoscopy and GI therapeutics.
CEO Giovanni Di Napoli emphasized DDW's importance as the epicenter of GI innovation. The company has also convened its AI Advisory Board at the event to guide strategic priorities and accelerate development across its AI platform. Cosmo's participation demonstrates its commitment to advancing GI care through technology integration and strategic partnerships.
Cosmo (CMOPF) parteciperà a Digestive Disease Week® (DDW) 2025, che si terrà a San Diego, California, dal 3 al 6 maggio. Il team dirigenziale dell'azienda sta conducendo incontri strategici con opinion leader, innovatori e potenziali partner nel campo dell'intelligenza artificiale e dello sviluppo di farmaci gastrointestinali (GI). DDW, che ogni anno richiama oltre 13.000 gastroenterologi, ricercatori e leader del settore, rappresenta una piattaforma fondamentale per Cosmo per rafforzare la sua posizione nell'endoscopia potenziata dall'IA e nelle terapie GI.
Il CEO Giovanni Di Napoli ha sottolineato l'importanza di DDW come epicentro dell'innovazione gastrointestinale. In occasione dell'evento, l'azienda ha inoltre riunito il suo Consiglio Consultivo sull'IA per definire le priorità strategiche e accelerare lo sviluppo della sua piattaforma AI. La partecipazione di Cosmo dimostra il suo impegno a migliorare la cura gastrointestinale attraverso l'integrazione tecnologica e partnership strategiche.
Cosmo (CMOPF) participará en Digestive Disease Week® (DDW) 2025, que se celebrará en San Diego, California, del 3 al 6 de mayo. El equipo directivo de la empresa está llevando a cabo reuniones estratégicas con líderes de opinión, innovadores y posibles socios en el ámbito de la inteligencia artificial y el desarrollo de medicamentos gastrointestinales (GI). DDW, que atrae anualmente a más de 13,000 gastroenterólogos, investigadores y líderes de la industria, sirve como plataforma para que Cosmo fortalezca su posición en endoscopias impulsadas por IA y terapias GI.
El CEO Giovanni Di Napoli destacó la importancia de DDW como epicentro de la innovación gastrointestinal. La empresa también ha convocado a su Junta Asesora de IA durante el evento para orientar las prioridades estratégicas y acelerar el desarrollo de su plataforma de IA. La participación de Cosmo demuestra su compromiso con el avance del cuidado gastrointestinal mediante la integración tecnológica y alianzas estratégicas.
Cosmo (CMOPF)는 2025년 5월 3일부터 6일까지 캘리포니아 샌디에이고에서 열리는 Digestive Disease Week® (DDW) 2025에 참가합니다. 회사의 경영진은 인공지능(AI) 및 위장관(GI) 약물 개발 분야의 주요 의견 리더, 혁신가 및 잠재 파트너들과 전략적 회의를 진행하고 있습니다. 매년 13,000명 이상의 위장병 전문의, 연구원 및 업계 리더들이 참여하는 DDW는 Cosmo가 AI 기반 내시경 및 GI 치료제 분야에서 입지를 강화할 수 있는 플랫폼입니다.
CEO Giovanni Di Napoli는 DDW가 GI 혁신의 중심지임을 강조했습니다. 회사는 행사 기간 동안 AI 자문위원회를 소집하여 전략적 우선순위를 설정하고 AI 플랫폼 개발을 가속화하고 있습니다. Cosmo의 참여는 기술 통합과 전략적 파트너십을 통해 GI 치료 발전에 대한 의지를 보여줍니다.
Cosmo (CMOPF) participe à la Digestive Disease Week® (DDW) 2025, qui se tiendra à San Diego, Californie, du 3 au 6 mai. L'équipe dirigeante de l'entreprise mène des réunions stratégiques avec des leaders d'opinion, des innovateurs et des partenaires potentiels dans le domaine de l'intelligence artificielle et du développement de médicaments gastro-intestinaux (GI). DDW, qui attire chaque année plus de 13 000 gastro-entérologues, chercheurs et leaders industriels, constitue une plateforme pour Cosmo afin de renforcer sa position dans l'endoscopie assistée par IA et les thérapies GI.
Le PDG Giovanni Di Napoli a souligné l'importance de DDW en tant qu'épicentre de l'innovation GI. L'entreprise a également réuni son conseil consultatif en IA lors de l'événement pour orienter les priorités stratégiques et accélérer le développement de sa plateforme IA. La participation de Cosmo témoigne de son engagement à faire progresser les soins GI grâce à l'intégration technologique et à des partenariats stratégiques.
Cosmo (CMOPF) nimmt an der Digestive Disease Week® (DDW) 2025 teil, die vom 3. bis 6. Mai in San Diego, Kalifornien, stattfindet. Das Führungsteam des Unternehmens führt strategische Gespräche mit Meinungsführern, Innovatoren und potenziellen Partnern im Bereich Künstliche Intelligenz und gastrointestinale (GI) Arzneimittelentwicklung. DDW, die jährlich über 13.000 Gastroenterologen, Forscher und Branchenführer anzieht, bietet Cosmo eine Plattform, um seine Position in der KI-gestützten Endoskopie und GI-Therapeutika zu stärken.
CEO Giovanni Di Napoli betonte die Bedeutung der DDW als Zentrum für GI-Innovationen. Das Unternehmen hat zudem während der Veranstaltung seinen KI-Beirat einberufen, um strategische Prioritäten zu setzen und die Entwicklung seiner KI-Plattform zu beschleunigen. Cosmos Teilnahme unterstreicht das Engagement, die GI-Versorgung durch technologische Integration und strategische Partnerschaften voranzutreiben.
- None.
- None.
Dublin, Ireland--(Newsfile Corp. - May 5, 2025) - Cosmo is attending this year’s Digestive Disease Week® (DDW), held in San Diego, California from May 3-6, where its leadership team is advancing a focused agenda of strategic meetings with key opinion leaders (KOLs), innovators, and potential partners in AI and gastrointestinal (GI) drug development.
DDW is the world’s premier gathering in the field, attracting each year over 13,000 gastroenterologists, researchers, and industry leaders from around the globe. Cosmo is leveraging this unique setting to deepen relationships and explore new collaborations that align with its strategy to lead in AI-powered endoscopy and GI therapeutics.
“DDW is the epicentre of innovation in GI, and we are here to make meaningful progress,” said Giovanni Di Napoli, CEO of Cosmo. “We’re engaging with some of the brightest minds and most visionary partners to drive our AI and drug development efforts forward. The future of GI is being shaped now, and Cosmo is committed to being a catalyst in that transformation.”
In parallel, Cosmo has convened its AI Advisory Board at DDW, bringing together world-class experts to guide the company’s strategic priorities and fast-track development across its AI platform.
Cosmo’s presence at the Digestive Disease Week® underscores its long-term commitment to advancing GI care through a unique integration of technology, science, and execution. The Company continues to invest in partnerships that will unlock new value for physicians and patients across the globe.
About Cosmo
Cosmo Pharmaceuticals N.V. is committed to revolutionizing healthcare and transforming people’s lives by researching and developing innovative products that tackle unfulfilled healthcare demands. As a pharmaceutical company, Cosmo is active in the areas of Healthtech/AI, dermatology, gastroenterology and contract manufacturing & development. For the commercialization and distribution of its products, Cosmo collaborates with leading partners worldwide, including Medtronic and Sun Pharma. Founded in 1997, Cosmo is headquartered in Dublin (Ireland) and has offices also in San Diego (USA), and Lainate/Rome/Catania (Italy). The Company has approximately 330 employees at the end of 2024, all dedicated to making a significant impact in the field of healthcare. For more information, please visit www.cosmopharma.com.
Financial calendar
| Ordinary Annual General Meeting of Shareholders | May 30, 2025 |
| Jefferies Healthcare Conference, New York | June 3-5, 2025 |
| Investor Day, Zurich | July 1, 2025 |
| 2025 Half-Year Results and Report | July 23, 2025 |
For further information, please contact:
Cosmo Pharmaceuticals Investor Relations, investor.relations@cosmopharma.com
Disclaimer
Some of the statements in this press release may be forward-looking statements or statements of future expectations based on currently available information. Such statements are naturally subject to risks and uncertainties. Factors such as the development of general economic conditions, future market conditions, unusual catastrophic loss events, changes in the capital markets and other circumstances may cause the actual events or results to be materially different from those anticipated by such statements. Cosmo does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such statements. Therefore, in no case whatsoever will Cosmo and its affiliate companies be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages.
Attachments
250505_Cosmo Pharma_Media Release_DDW 2025_EN_final
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/250781
FAQ
What is Cosmo's (CMOPF) main focus at Digestive Disease Week 2025?
When and where is Digestive Disease Week 2025 being held?
Who is the CEO of Cosmo (CMOPF) and what did he say about DDW 2025?
What are Cosmo's (CMOPF) strategic priorities in gastrointestinal care?
